SG11202004234SA - A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition - Google Patents

A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Info

Publication number
SG11202004234SA
SG11202004234SA SG11202004234SA SG11202004234SA SG11202004234SA SG 11202004234S A SG11202004234S A SG 11202004234SA SG 11202004234S A SG11202004234S A SG 11202004234SA SG 11202004234S A SG11202004234S A SG 11202004234SA SG 11202004234S A SG11202004234S A SG 11202004234SA
Authority
SG
Singapore
Prior art keywords
immunogenic composition
structural proteins
zika virus
chimeric polyepitope
virus chimeric
Prior art date
Application number
SG11202004234SA
Inventor
Claude Roth
Etienne Simon-Loriere
Anavaj Sakuntabhai
Felix Delgado
Original Assignee
Pasteur Institut
Univ El Bosque
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ El Bosque filed Critical Pasteur Institut
Publication of SG11202004234SA publication Critical patent/SG11202004234SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202004234SA 2017-11-09 2018-11-08 A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition SG11202004234SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306553 2017-11-09
PCT/EP2018/080677 WO2019092142A1 (en) 2017-11-09 2018-11-08 A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Publications (1)

Publication Number Publication Date
SG11202004234SA true SG11202004234SA (en) 2020-06-29

Family

ID=60574493

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004234SA SG11202004234SA (en) 2017-11-09 2018-11-08 A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Country Status (12)

Country Link
US (2) US11305003B2 (en)
EP (1) EP3707154A1 (en)
JP (1) JP7225254B2 (en)
KR (1) KR20200090186A (en)
CN (1) CN111683959A (en)
AU (1) AU2018365296B2 (en)
BR (1) BR112020009157A2 (en)
CA (1) CA3079776A1 (en)
MX (1) MX2020004833A (en)
PH (1) PH12020550569A1 (en)
SG (1) SG11202004234SA (en)
WO (1) WO2019092142A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN113528465B (en) * 2020-04-20 2023-07-11 中国人民解放军军事科学院军事医学研究院 DNA molecule containing mutant Zika virus whole genome cDNA and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233038D1 (en) 2002-06-20 2009-09-03 Pasteur Institut Infectious cDNA of an approved measles virus vaccine strain. Use in immunogenic compositions
ES2427139T3 (en) 2002-06-20 2013-10-29 Institut Pasteur Recombinant measles viruses expressing epitopes of RNA virus antigens and use of recombinant viruses for the preparation of vaccine compositions
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
ES2423518T3 (en) 2006-12-22 2013-09-20 Institut Pasteur Cells and methodology to generate unsegmented negative sense chain RNA viruses
EP2185192B1 (en) 2007-08-03 2018-10-31 Institut Pasteur Lentiviral gene transfer vectors and their medicinal applications
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
EP2959915A1 (en) 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
GB201508099D0 (en) * 2015-05-12 2015-06-24 Isis Innovation Dengue vaccines
WO2016209805A1 (en) 2015-06-22 2016-12-29 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
WO2018009603A1 (en) * 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
WO2018071405A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
AU2017405996A1 (en) * 2017-03-27 2019-10-10 The University Of Queensland Chimeric insect-specific flaviviruses
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Also Published As

Publication number Publication date
CA3079776A1 (en) 2019-05-16
US11872276B2 (en) 2024-01-16
US11305003B2 (en) 2022-04-19
MX2020004833A (en) 2021-01-08
JP2021502115A (en) 2021-01-28
CN111683959A (en) 2020-09-18
AU2018365296A1 (en) 2020-05-21
EP3707154A1 (en) 2020-09-16
US20200282043A1 (en) 2020-09-10
KR20200090186A (en) 2020-07-28
BR112020009157A2 (en) 2020-10-27
PH12020550569A1 (en) 2021-04-19
JP7225254B2 (en) 2023-02-20
US20220233678A1 (en) 2022-07-28
WO2019092142A1 (en) 2019-05-16
AU2018365296B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
HUS2300022I1 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
ZA201701851B (en) Fmdv recombinant vaccines and uses thereof
HK1231490A1 (en) Modified antigen binding polypeptide constructs and uses thereof
SG11201610731VA (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
HK1246318A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
SG11202004234SA (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
IL264009A (en) Antibodies with low immunogenicity and uses thereof
IL249368A0 (en) Map44 polypeptides and constructs based on natural antibodies and uses thereof
HK1257191A1 (en) Recombinant turkey herpesvirus vaccines and uses thereof
SG10201912925SA (en) Antibodies that bind zika virus envelope protein and uses thereof
HK1205148A1 (en) Proteins and methods used to prepare hepatitis e virus-like particles
HUE063274T2 (en) Oncolytic virus and method
HK1258695A1 (en) Fmdv and e2 fusion proteins and uses thereof
EP3013852A4 (en) Methods and compositions for dengue virus vaccines
EP3664846A4 (en) Antibody to epstein barr virus and uses thereof
EP3131875A4 (en) Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
SG11201606237RA (en) Hcv chimeric vaccine with influenza virus as vector and preparation method thereof
EP2868665A4 (en) Hepatitis c virus b cell epitope peptide puhi26 and applications thereof
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201707286D0 (en) Improvements in or relating to vaccines and bac cloning
TH1501005277A (en) Composition and methods for dengue virus chimeric constructs in vaccines.
GB201619551D0 (en) Prokaryotic Argonaute proteins and uses thereof
GB201612090D0 (en) Prokaryotic argonaute proteins and uses thereof